Biothera

About Biothera

Biothera Pharmaceuticals is a clinical-stage biotechnology company focused on the development of cancer treatments. The company's main focus is on immuno-oncology, a field of medicine that uses the body's own immune system to fight cancer.

Biothera's lead product candidate is Imprime PGG, a proprietary immunotherapy that is being evaluated in clinical trials for the treatment of various cancers, including head and neck cancer. The company is collaborating with AstraZeneca to evaluate the combination of Imprime PGG with durvalumab, an immune checkpoint inhibitor, in a Phase 2 clinical trial.

In addition to Imprime PGG, Biothera is also developing a pipeline of other immuno-oncology drug candidates, including monoclonal antibodies. The company's business model is focused on research and development, and it collaborates with larger pharmaceutical companies to conduct clinical trials and commercialize its products.